Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization.

Elham Rahme,Hacene Nedjar,Waqqas Afif

Journal of the Canadian Association of Gastroenterology（2020）

Cited 0|Views15
No score
Abstract
In patients with severe refractory CD on off-label ustekinumab, approximately 60% remained on treatment beyond 1 year. The cost of gastrointestinal services did not increase during that year as compared to that of the year preceding ustekinumab use.
More
Translated text
Key words
Administrative data,Chron’s disease,Direct medical cost,Health services utilization,Refractory,Ustekinumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined